Пиодермии в амбулаторной практике | КМАХ

Пиодермии в амбулаторной практике

Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(3):255-270

​ Белькова Ю.А.
пиодермия инфекции кожи Staphylococcus aureus Streptococcus pyogenes
Раздел
Болезни и возбудители
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(3):255-270

Аннотация

Несмотря на широкое внедрение в клиническую практику антибактериальных препаратов, пиодермии остаются важной проблемой современной медицины. В экономически развитых странах инфекции кожи и мягких тканей, в том числе пиодермии, составляют 1⁄3 всех инфекционных заболеваний. В последние годы особую озабоченность вызывает рост антибиотикорезистентности основных возбудителей пиодермий — Staphylococcus aureus и Streptococcus pyogenes, что во многом обусловлено нерациональным и бесконтрольным применением антимикробных препаратов. При общем обсуждении вопросов эпидемиологии пиодермий в амбулаторных условиях подробно рассматриваются проблемы этиологии и лечения инфекций данной группы.

  • 1. Jones M.E., Karlowsky J.A., Draghi D.C., Thornsberry C., Sahm D.F., Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tisue infections in the USA and Europe: a guide to appropriate antimicrobial treatment. Int J Antimicrob Agent 2003; 22:406-19.
  • 2. Каламкарян А.А., Архангельская Е.И., Глухень - кий Б.Т. Кожные и венерические болезни. Руководство для врачей. Москва: Медицина; 1995. Том 1. с. 256-87.
  • 3. Масюкова С.А., Гладько В.В., Устинов М.В., Вла димирова Е.В., Тарасенко Г.Н., Сорокина Е.В. Бактериальные инфекции кожи и их значение в клинической практике дерматолога. Consilium medicum 2004; 6(3):180-5.
  • 4. Новиков А.И., Логинова Э.А. Болезни кожи инфекционного и паразитарного происхождения. Руководство для врачей. Москва: Медцинская книга; 2001.
  • 5. Новосёлов В.С., Плиева Л.Р. Пиодермии. РМЖ 2004; 12(5):327-35.
  • 6. Korting H.C., Neubert U., Abeck D. Current antimicrobial susceptibility of cutaneous bacteria to first line antibiotics. Int J Antimicrob Agents 1998; 10(2):165-8.
  • 7. Иванова О.Л. Кожные и венерические болезни. Москва: Медицина; 1997. с. 197-200.
  • 8. Каламкарян А.А., Архангельская Е.И., Глухенький Б.Т., Масюкова С.А. Гнойничковые заболевания кожи. В кн.: Скрипкин Ю.К., Мордовцева В.Н., ред. Кожные и венерические болезни. 2 изд. Москва: Медицина; 1999. Том 1. с. 213-57.
  • 9. Кулагин В.И., Селисский Г.Д., Пономарев Б.А., Зуева И.В., Кравец Т.А. Вклад отечественных исследователей в учение о пиодермитах. Российский журнал кожных и венерических болезней 2000; 5:62-4.
  • 10. Eron L.J., Lipsky B.A., Low D.E., Nathwani D., Tice A.D., Volturo G.A. Managing skin and soft tissue infection: expert panel recommendations key decision points. J Antimicrob Chemother 2003; 52(Suppl.S1):i3-i17.
  • 11. Failla D.M., Pankey G.A. Optimum outpatient therapy of skin and skin structure infections. Drugs 1994; 48(2):172-8.
  • 12. Swartz M.N., Pasternack M.S. Cellulitis and subcutaneous tissue infection. In: Mandell G.L., Bennett J.E., Dolin R., editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingston; 2005.p.1172-1193.
  • 13. Троицкая А.Д. Пиодермиты (стафилодермии и стрептодермии). Ленинград: Медгиз; 1958.
  • 14. Moreillon P., Que Y.-A., Glauser M.P. Staphylococcus aureus (Including Staphylococcal Toxic Shock). In: Mandell G.L., Bennett J.E., Dolin R., ed. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingston; 2005. p.2321-51.
  • 15. Rennie R.P., Jones R.N., Mutnick A.H.; SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003; 45(4):287-93.
  • 16. Sader H.S., Jones R.N., Silva J.B.; SENTRY Participants Group (Latin America). Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis 2002; 44(3):281-8.
  • 17. US Food and Drug Administration. Uncomplicated and Complicated Skin and Skin Structure Infections – Developing Antimicrobial Drugs for Treatment. Guidance for industry. 1998.
  • 18. University of Michigan Hospitals and Health Centers. Guidelines for determining presence and classification of infections. Available from: URL: http://www.med. umich.edu/ice/defs/
  • 19. Noble W.C. Microbiology of human skin. 2nd ed. London, Lloyd-Luke, 1981.
  • 20. Roth R.R., James W.D. Microbiology of the skin: resident flora, ecology, infection. J Am Acad Dermatol 1989; 20(3):367-90.
  • 21. Archer G.L., Climo M.W. Staphylococcus epidermidis and other coagulase-negative staphylococci. In: Man - dell G.L., Bennett J.E., Dolin R., ed. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingston; 2005. p. 2352-59.
  • 22. Hirschmann J.V., Feingold D.S. Normal cutaneous flora and infections they cause. In: Gorbach S.L., Bartlett J.G., Blacklow N.R., ed. Infectious diseases. 2nd ed. Philadelphia: W.B. Saunders Company; 1998.p.1263-5.
  • 23. Weems J.J., Beck L.B. Nasal Carriage of Staphylococcus aureus as a risk factor for skin and soft tissue infections. Curr Infect Dis Rep 2002; 4(5):420-5.
  • 24. Sanford M.D., Widmer A.F., Bale M.J., Jones R.N., Wenzel R.P. Efficient detection and long-term persistance of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1994; 19:1123-8.
  • 25. Tuazon C.U., Perez A., Kishaba T., Sheagren J.N. Staphylococcus aureus among insulin-injecting diabetic patients: an increased carrier rate. JAMA 1975; 231:1272.
  • 26. Weinke T., Schiller R., Fehrenbach F.J., Pohle H.D. Association between Staphylococcus aureus nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1992; 11:985-9.
  • 27. Tuazon C.U., Sheagren J.N. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 1974; 129:725-7.
  • 28. Kluytmans J.A., Mouton J.W., Ijzerman E.P., Vandenbroucke-Grauls C.M., Maat A.W., Wagenvo - ort J.H., et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995; 171:216-9.
  • 29. Фицпатрик Т., Джонсон Р., Вулф К., Полано М., Сюрмонд Д. Дерматология. Атлас-справочник. Москва: Практика; 1999.
  • 30. Ferrieri P., Dajani A.S., Wannamaker L.W., Chapman S.S. Na tural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. J Clin Invest 1972; 51:2851-62.
  • 31. Гучев И.А., Сидоренко С.В., Французов В.Н. Рациональная антимикробная химиотерапия инфекций кожи и мягких тканей. Антибиотики и химиотерапия 2003; 48(10):25-31.
  • 32. Bowler P.G., Duerden B.I., Armstrong D.G. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14:244-69.
  • 33. Chamberlain N.R. The Microbiology of Wounds. Available from: URL: www.kcom.edu/faculty/chamberlain/Website/wound/wound.PPT
  • 34. Elston D.M. Epidemiology and prevention of skin and soft tissue infections. Cutis 2004; 73(Suppl 5):3-7.
  • 35. Murakawa G.J. Common pathogens and differential diagnosis of skin and soft tissue infections. Cutis 2004; 73(Suppl5):7-10.
  • 36. Tarshis G.A., Miskin B.M., Jones T.M., Champlin J., Wingert K.J., Breen J.D., et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, mulicenter, randomized study. Antimicrob Agent Chemother 2001; 45(8):2358-62.
  • 37. Classics in infectious diseases: «On abscesses»: Alexan - der Ogston (1844-1929). J Infect Dis 1984; 6:122-8.
  • 38. Ogston A. Micrococcus poisoning. J Anat 1882; 17:24-58.
  • 39. Foster T.J., Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998; 6(12):484-8.
  • 40. Siboo I.R., Cheung A.L., Bayer A.S., Sullam P.M. Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect Immun 2001; 69(5):3120-7.
  • 41. Ni Eidhin D., Perkins S., Francois P., Vaudaux P., Hook M., Foster T.J. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol Microbiol 1998; 30(2):245-57.
  • 42. Chavakis T., Hussain M., Kanse S.M., Peters G., Bretzel R.G., Flock J.I., et al. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat Med 2002; 8(7):687-93.
  • 43. Downer R., Roche F., Park P.W., Mecham R.P., Foster T.J. The elastin-binding protein of Staphylococcus aureus (EbpS) is expressed at the cell surface as an integral membrane protein and not as a cell wall-associated protein. J Biol Chem 2002; 277(1):243-50.
  • 44. Gotz F. Staphylococcus and biofilms. Mol Microbiol 2002; 43(6):1367-78.
  • 45. Cunnion K.M., Lee J.C., Frank M.M. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun 2001; 69(11):6796-6803.
  • 46. Hartleib J., Kohler N., Dickinson R.B., Chhatwal G.S., Six ma J.J., Hartford O.M., et. al. Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood 2000; 96(6):2149-56.
  • 47. Dubin G. Extracellular proteases of Staphylococcus spp. Biol Chem 2002; 383:1075-86.
  • 48. Makris G., Wright J.D., Ingham E., Holland K.T. The hyaluronate lyase of Staphylococcus aureus – a virulence factor? Microbiology 2004; 150:2005-13.
  • 49. Rosenstein R., Gotz F. Staphylococcal lipases: biochemical and molecular characterization. Biochimie 2000; 82(11):1005-14.
  • 50. Parry M.A., Zhang X.C., Bode I.. Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem Sci 2000; 25(2):53-9.
  • 51. Dinges M.M., Orwin P.M., Schlievert P.M. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000; 13(1):16-34.
  • 52. Ladhani S. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Immunol Med Microbiol 2003; 39(2):181-9.
  • 53. Frazee B.W., Lynn J., Charlebois E.D., Lambert L., Lowery D., Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann emerg Med 2005; 45(3):311-20.
  • 54. Katayama Y., Ito T., Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44:1549-55.
  • 55. Bisno A.L., Stevens D.L. Streptococcus pyogenes. In: Mandell G.L., Bennett J.E., Dolin R., editors. Mandell, Do ug las, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingston; 2005. p. 2362-79.
  • 56. Brown J.H. The use of blood agar for the study of streptococci. New York: The Rockfellers Institute of Medical Research; 1919.
  • 57. Lancefield R.C. A serological differentiation of human and other groups of hemolytic streptococci. J Exp Med 1933; 57:571-95.
  • 58. Kreikemeyer B., Oehmcke S., Nakata M., Hoffrogge R., Podbielski A. Streptococcus pyogenes fibronectin-binding protein F2: expression profile, binding characteristics, and impact on eukaryotic cell interactions. J Biol Chem 2004; 279(16):15850-9.
  • 59. Toppel A.W., Rasmussen M., Rohde M., Medina E., Chhatwal G.S. Contribution of protein G-related α2-macroglobulin-binding protein to bacterial virulence in a mouse skin model of group A streptococcal infection. J Infect Dis 2003; 187(11):1694-1703.
  • 60. Bisno A.L., Brito M.O., Collins C.M. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 2003; 3(4):191-200.
  • 61. Berggard K., Johnsson E., Morfeldt E., Persson J., Stalhammar-Carlemalm M., Lindahl G.K. Binding of human C4BP to the hypervariable region of M protein: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes. Mol Microbiol 2001; 42(2):539-51.
  • 62. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13(3):470-511.
  • 63. Frick I.M., Akesson P., Rasmussen M., Schmidtchen A., Bjorck L.. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 2003; 278(19):16561-6.
  • 64. Anderson E.T., Wetherell M.G., Winter L.A., Olms - ted S.B., Cleary P.P., Matsuka Y.V. Processing, stability, and kinetic parameters of C5a peptidase from Streptococcus pyogenes. Eur J Biochem 2002; 269(19):4839-51.
  • 65. Hynes W.L., Walton S.L. Hyaluronidases of Gram-positive bacteria. FEMS Microbiol Lett 2000; 183(2):201-7.
  • 66. Von Pawel-Rammingen U., Bjorck L. IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr Opin Microbiol 2003; 6(1):50-5.
  • 67. Collin M., Olsen A. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun 2001; 69(11):7187-9.
  • 68. Svensson M.D., Sjobring U., Luo F., Bessen D.E. Roles of the plasminogen activator streptokinase and the plasminogen-associated M protein in an experimental model for streptococcal impetigo. Microbiology 2002; 148:3933-45.
  • 69. Mitchell T.J. The pathogenesis of streptococcal infections: from tooth decay to meningitis. Nat Rev Microbiol 2003; 1(3):219-30.
  • 70. McCormick J.K., Pragman A.A., Stolpa J.C., Leung D.Y., Schlievert P.M.. Functional characterization of streptococcal pyrogenic exotoxin J, a novel superantigen. Infect Immun 2001; 69(3):1381-8.
  • 71. WHO Model Prescribing Information — Drugs used in bacterial infections. Available from: URL: http://www.who.int/medicines/library/bacterial_model_pres/bacterial_content.shtml
  • 72. Doern G.V., Jones R.N., Pfaller M., Kugler K., Beach M.L. and The SENTRY study group. Bacterial pathogens isolated from patients with skin and soft tissue infections: Frequency of occurrence and antimicrobial susceptibility patterns from SENTRY antimicrobial surveillance program (USA and Canada, 1997). Diagn Microbiol Infect Dis 1999; 34:65-72.
  • 73. Jones P.G., Sura T., Harris M., Strother A. Mupirocin resistance in clinical isolates of Staphylococcus aureus. Infect Control Hosp Epidemiol 2003; 24(4):300-1.
  • 74. Nishijima S., Kurokawa I. Antimicrobial resistance of Staphylococcus aureus isolated from skin infections. Int J Antimicrob Agents 2002; 19(3):241-3.
  • 75. Schmitz F.J., Lindenlauf E., Hofmann B., Fluit A.C., Verhoef J., Heinz H.P., et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998; 42(4):489-95.
  • 76. Moorhouse E., Fenelon L., Hone R., Smyth E., McGahon J., Dillon M. Staphylococcus aureus sensitivity to various antibiotics – a national survey in Ireland 1993. Ir J Med Sci 1996; 165:40-3.
  • 77. Toma E., Barriault D. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for Gram-positive cocci. J Clin Microbiol 1995; 33:1712-5.
  • 78. Turnidge J., Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12 (Suppl 2):35-44.
  • 79. Страчунский Л.С., Дехнич А.В., Белькова Ю.А. Сравни тельная активность антибактериальных препаратов, входящих в лекарственные формы для местного применения, в отношении Staphylococcus aureus: результаты российского многоцентрового исследования. Клин микробиол антимикроб химиот 2002; 4(2):157-64.
  • 80. Eady E.A, Cove J.H. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus – an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003; 16(2):103-24.
  • 81. Gosbell I.B. Methicillin-resistant Staphylococcus aureus: impact on dermatology practice. Am J Clin Dermatol 2004; 5(4):239-59.
  • 82. Young D.M., Harris H.W., Charlebois E.D., Chambers H., Campbell A., Perdreau-Remington F., et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004; 139(9):947-51.
  • 83. Salgado C.D., Farr B.M., Calfee D.P. Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36:131-9.
  • 84. Fey P.D., Said-Salim B., Rupp M. E., Hinrichs S.H., Boxrud D.J., Davis C.C., et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47(1):96-203.
  • 85. Okuma K., Iwakawa K., Turnidge J.D., Grubb W.B., Bell J.M., O’Brien F.G., et al. Dissemination of new methi cillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40(11):4289-94.
  • 86. Prevost G., Couppie P., Prevost P., Gayet S., Petiau P., Cribier B., et al. Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995; 42:237-45.
  • 87. Lina G., Piémont Y., Godail-Gamot F., Bes M., Peter M., Gauduchon V., et al. Involvement of Panton-Valentine leukocidin producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-32.
  • 88. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections – Los Angeles County, California, 2002-2003. MMWR 2003; 52(5):88.
  • 89. Soriano F., Granizo J.J., Fernandez-Roblas R., Esteban J., Gadea I., Gracia M., et al. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from adult patients with respiratory tract and skin and soft tissue infections in four southern European countries. J Chemother 2003; 15(3):293-5.
  • 90. Козлов Р.С., Сивая О.В., Шпынев К.В., Агапова Е.Д., Розанова С.М., Гугуцидзе Е.Н., и др. Антибиотикорез истентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. Клиническая Микробиология и Антимикробная Химиотерапия 2002; 4(2):154-67.
  • 91. Seppälä H., Nissinen A., Jarvinen H., Huovinen S., Henriksson T., Herva E. et al. Resistance to erythromycin in group A streptococci. New England Journal of Medicine 1992; 326:292-7.
  • 92. Практическое руководство по антиинфекционной химиотерапии. Страчунский Л. С., Белоусов Ю. Б., Козлов С. Н., ред. Москва; 2002.
  • 93. Pocket Book of Infectious Disease Therapy. Bartlett J.G., editor. Williams&Wilkins; 1998.
  • 94. Antimicrobial Therapy Guide. Meyers B.R., editor. 16th ed. Newtown: Antimicrobial Prescribing, Inc; 2004.
  • 95. The Sanford Guide to Antimicrobial Therapy. Gilbert D.N., Moellering R.C. Jr., Eliopoulos G.M., Sande M.A. ed. 35rd ed. New York: Atimicrobial Therapy, Inc; 2005.
  • 96. Богданович Т.М., Страчунский Л.С. Мупироцин: Уникальный антибиотик для местного применения. Клиническая Микробиология и Антимикробная Химиотерапия 1999; 1(1):57-65.
  • 97. Kraus S.J., Eron L.J., Bottenfield G.W., Drehobl M.A., Bushnell W.D., Cupo M.A. Mupirocin cream is as effective as oral cephalexin in the treatment of secondarily infected wounds. J Fam Pract 1998; 47(6):429-33.
  • 98. Breneman D.L. Use of mupirocin ointment in the treatment of secondarily infected dermatoses. J Am Acad Dermatol 1990; 22(5):886-92.
  • 99. Villiger J.W., Robertson W.D., Kanji K., Ah Chan M., Fetherston J., Hague I.K., et al. A comparison of the new topical antibiotic mupirocin (‘Bactroban’) with oral antibiotics in the treatment of skin infections in general practice. Current Med Res Opinion 1986; 10(5):339-45.
  • 100. White D.G., Collins P.O., Rowsell R.B. Topical antibiotics in the treatment of superficial skin infections in general practice--a comparison of mupirocin with sodium fusidate. J Infect 1989; 18(3):221-9.
  • 101. Wong K.S., Lim K.B., Tham S.N., Ling M.L., Tan T. Comparative double-blinded study between mupirocin and tetracycline ointments for treating skin infections. Singapore Med J 1989; 30(4):380-3.
  • 102. Dagan R., Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children. Antimicrob Agents Chemother 1992; 36(2):287-90.
  • 103. Rist T., Parish L.C., Capin L.R., Sulica V., Bushnell W.D., Cu po M.A. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol 2002; 27(1):14-20.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились